Real-World data shows promise for kidney cancer drug combo
NCT ID NCT04941768
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how well avelumab (BAVENCIO) plus axitinib (INLYTA) works for advanced kidney cancer in everyday medical practice. Researchers tracked 105 patients across multiple EU countries to see survival rates at 12 and 24 months. The goal was to understand the treatment's effectiveness and safety outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avelumab (BAVENCIO) and axitinib (INLYTA)
What this could lead to
If results are positive, this could confirm that the combination is effective for advanced kidney cancer in real-world settings, supporting its use as a standard first-line therapy.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. The small size (105 participants) and lack of a comparison group limit how much we can conclude.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ KLINA
Brasschaat, Belgium
-
AZ Sint-Jan
Bruges, Belgium
-
Agios Loukas Hospital
Thessaloniki, Greece
-
Attikon
Chaïdári, Greece
-
Attikon Hospital
Attiki, Greece
-
Biberach
Biberach an der Riss, Germany
-
Bioclinic (GRC)
Thessaloniki, Greece
-
Donauisar Klinikum Deggendorf
Deggendorf, Germany
-
Evangelisches Klinikum Bethel
Bielefeld, Germany
-
Evangelisches Krankenhaus Bielefeld
Bielefeld, Germany
-
GPR Klinikum Rüsselsheimg GmbH
Rüsselsheim am Main, Germany
-
Gen. Hos. "Alexandra"
Athens, Greece
-
General Hospital "Venizelio"
Heraklion, Greece
-
General Hospital of Athens G.Gennimatas
Athens, Greece
-
General Hospital of Patras "o Agios Andreas"
Pátrai, Greece
-
Henry Dunant Hospital Center
Athens, Greece
-
Hämatologie und Onkologie Stolberg
Stolberg, Germany
-
Imelda Ziekenhuis
Bonheiden, Belgium
-
Johannes Wesling Klinikum Minden der Mühlenkreiskliniken (AöR)
Minden, Germany
-
Kavala General Hospital
Kavala, Greece
-
Klinikum Aschaffenburg Medizinische Klinik
Aschaffenburg, Germany
-
Klinikum Friedrichshafen GmbH daVinci® -Zentrum Bodensee
Friedrichshafen, Germany
-
Klinikum Osnabrück GmbH
Osnabrück, Germany
-
Klinikum St. Marien Amberg
Amberg, Germany
-
Lahn Dill Kliniken GmbH
Wetzlar, Germany
-
MVZ Onkologische Kooperation Harz GbR
Goslar, Germany
-
Marienhospital Osnabrück - Standort Natruper Holz
Osnabrück, Germany
-
Medizinische Hochschule Hannover
Hanover, Germany
-
Medizinische Studiengesellschaft Nord-West GmbH
Westerstede, Germany
-
Metaxa Hospital
Piraeus, Greece
-
Metropolitan Hospital Greece
Piraeus, Greece
-
Onkologische GP Dres. Wilke/Wagner/Petzoldt
Fürth, Germany
-
Onkologische SP Praxis Fürth
Fürth, Germany
-
Papageorgiou Hospital
Thessaloniki, Greece
-
Paracelsus Klinik Osnabrück
Osnabrück, Germany
-
Praxis Dr. Maas
Halberstadt, Germany
-
Praxis Kretz
Heinsberg, Germany
-
Praxis Troisdorf
Troisdorf, Germany
-
Regional Oncology Dispensary - Irkutsk
Irkutsk, Russia
-
SRH Kliniken Landkreis Sigmaringen (DEU)
Sigmaringen, Germany
-
Saint Luke Hospital
Thessaloniki, Greece
-
Schwerpunktpraxis für Hämatologie und Onkologie
Magdeburg, Germany
-
St. Georg Klinikum Eisenach gGmbH
Eisenach, Germany
-
Uniklinikum Münster
Münster, Germany
-
Universitaetsklinikum Essen Uroonkologie
Essen, Germany
-
Universitatsklinik Schleswig-Holstein
Lübeck, Germany
-
Universitatsklinikum Erlangen
Erlangen, Germany
-
University Hospital of Athens Sotiria
Athens, Greece
-
University Hospital of Ioannina
Ioannina, Greece
-
University Hospital of Larissa
Larissa, Greece
-
University of Munster
Münster, Germany
-
Universitätskinderklinik Jena
Jena, Germany
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
-
Urologie im Schlosscarree
Braunschweig, Germany
-
Urologische Gemeinschaftspraxis
Dresden, Germany
-
Urologische Praxis Dipl.-Med. Susanne Kloß
Luckenwalde, Germany
-
Urologische Praxis Dr. Ralf Eckert
L.-Eisleben, Germany
-
Vinzenzkrankenhaus Hannover
Hanover, Germany
-
Wissenschaftskontor Nord GmbH & Co. KG
Rostock, Germany
-
Zentrum für urologische Onkologie
Berlin, Germany
-
medius Klinik Ostfildern-Ruit
Ostfildren, Germany